» Articles » PMID: 32660903

Effects of Distance From Academic Cancer Center on Overall Survival of Acute Myeloid Leukemia: Retrospective Analysis of Treated Patients

Overview
Publisher Elsevier
Specialty Oncology
Date 2020 Jul 15
PMID 32660903
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Patients living farther away from academic centers may not have easy access to resources for management of acute myeloid leukemia (AML). We aimed to analyze the effect of distance traveled on overall survival (OS) of AML patients treated at an academic center.

Patients And Methods: AML patients diagnosed at the University of Nebraska Medical Center were divided into 4 groups according to the shortest distance between the cancer center and patients' residence (<25, 25-50, 50-100, and > 100 miles). Chi-square test and ANOVA were used to examine the association of distance with patient characteristics. OS, defined as the time from diagnosis of AML to death from any cause, was determined by the Kaplan-Meier method. Comparison of survival curves was done by the log-rank test. Multivariable analysis using Cox regression was performed to detect the survival effect of distance from the cancer center.

Results: The total number of patients was 449. Median distance was 85 miles (interquartile range, 20-180). OS at 1 year for < 25, 25-50, 50-100, and > 100 miles was 45%, 55%, 38%, and 40% respectively (P = .6). In a Cox regression analysis, distance from treatment center, as a continuous variable, was not a significant factor for death (hazard ratio, 1.001; 95% confidence interval, 1.000-1.001). Multivariable analysis showed nonsignificant trend of increased mortality for patients traveling > 100 miles to a cancer center.

Conclusion: This study did not demonstrate an association between distance from an academic cancer center and OS in AML. This finding should provide some assurance to patients who live farther away from academic centers.

Citing Articles

Residential Distance to the Cancer Center and Outcomes after Robotic-Assisted Pulmonary Lobectomy.

Dumitriu Carcoana A, Marek J, West 3rd W, Fiedler C, Doyle Jr W, Labib K Surg Pract Sci. 2025; 15():100210.

PMID: 39844799 PMC: 11749967. DOI: 10.1016/j.sipas.2023.100210.


Facility type and cancer outcomes in the United States.

Kilcoyne M, Nhim V, Gonzalez M, Olivas I, Eiring A Ann Cancer Epidemiol. 2024; 7.

PMID: 38468875 PMC: 10927266. DOI: 10.21037/ace-23-4.


Impact of socioeconomic disparities on outcomes in adults undergoing allogeneic hematopoietic cell transplantation for acute myeloid leukemia.

Olivieri D, Othus M, Orvain C, Rodriguez-Arboli E, Milano F, Sandmaier B Leukemia. 2024; 38(4):865-876.

PMID: 38388647 PMC: 10997459. DOI: 10.1038/s41375-024-02172-3.


Driving distances and loss to follow-up after hematopoietic cell transplantation.

Banerjee R, Loren A EJHaem. 2022; 2(2):272-275.

PMID: 35845266 PMC: 9175729. DOI: 10.1002/jha2.179.

References
1.
Bhatt V, Dhakal P, Dahal S, Giri S, Pathak R, Bociek R . Demographic and other characteristics of nodal non-Hodgkin's lymphoma managed in academic versus non-academic centers. Ther Adv Hematol. 2015; 6(5):223-7. PMC: 4556968. DOI: 10.1177/2040620715592568. View

2.
Hershenfeld S, Maki K, Rothfels L, Murray C, Nixon S, Schimmer A . Sharing post-AML consolidation supportive therapy with local centers reduces patient travel burden without compromising outcomes. Leuk Res. 2017; 59:93-96. DOI: 10.1016/j.leukres.2017.05.023. View

3.
Bhatt V, Chen B, Lee S . Use of hematopoietic cell transplantation in younger patients with acute myeloid leukemia: A National Cancer Database Study. Bone Marrow Transplant. 2018; 53(7):873-879. DOI: 10.1038/s41409-018-0105-9. View

4.
LENHARD Jr R, Enterline J, Crowley J, Ho G . The effects of distance from primary treatment centers on survival among patients with multiple myeloma. J Clin Oncol. 1987; 5(10):1640-5. DOI: 10.1200/JCO.1987.5.10.1640. View

5.
Bhatt V, Shostrom V, Gundabolu K, Armitage J . Utilization of initial chemotherapy for newly diagnosed acute myeloid leukemia in the United States. Blood Adv. 2018; 2(11):1277-1282. PMC: 5998918. DOI: 10.1182/bloodadvances.2018019125. View